Chlorotrianisene

This page contains recent news articles, when available, and an overview of Chlorotrianisene but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Chlorotrianisene (when available)

Pharmacology and use:
Chlorotrianisene is a nonsteroidal synthetic estrogen. After menopause, when the body no longer produces estrogen, chlorotrianisene is used as a simple replacement of estrogen. The estrogen-stimulated endometrium may bleed within 48-72 hours after discontinuance of estrogen therapy. Paradoxically, prolonged estrogen therapy may cause shrinkage of the endometrium and an increase in size of the myometrium. Estrogens have a weak anabolic effect and may cause sodium retention with associated fluid retention and edema. Estrogens may also decrease elevated blood cholesterol and phospholipid concentrations. Estrogens affect bone by increasing calcium deposition and accelerating epiphyseal closure, following initial growth stimulation. During the preovulatory or nonovulatory phase of the menstrual cycle, estrogen is the principal determinant in the onset of menstruation. A decline of estrogenic activity at the end of the menstrual cycle also may induce menstruation; however, the cessation of progesterone secretion is the most important factor during the mature ovulatory phase of the menstrual cycle. The benefit derived from estrogen therapy in the prevention of postpartum breast engorgement must be carefully weighed against the potential increased risk of puerperal thromboembolism associated with the use of large doses of estrogens. Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.

Mechanism Of Action:
Chlorotrianisene binds to the estrogen receptor on various estrogen receptor bearing cells. Target cells include cells in the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary.

News Articles on Chlorotrianisene

… Administrative Code - 77 Ill. Adm. Code 790.2420 CHLOROTRIANISENE …  -  Aug 10, 2005
77 Ill. Adm. Code 790.2420 CHLOROTRIANISENE (Repealed) Repealed. (Source: Repealed at 17 Ill. Reg. 15916, effective September 20, 1993) ... Pay-Per-View - Illinois Administrative Code - Loislaw

第174�?�第2款(《修正案》第3�?�)//伪造�?�?�造�?转让金�?机构�?�?�许�?��?�?批准...  -  Apr 26, 2007
12�?氯烯雌醚（Chlorotrianisene）�?�典2000年二部P919。 13�?炔诺醇（Ethinylestradiol） �?�典2000年二部P422。 14�?炔诺醚（Quinestrol）�?�典2000年二部P424。 ... 法制网

Georgia Code - 16-13-71. (a) A "dangerous drug" means any drug other ...  -  Aug 4, 2005
...(176) Chlorothiazide; (177) Chlorotrianisene; (178) Chloroxine; (179) Chlorphenesin; (180) Chlorpheniramine — See exceptions; (181) Chlorphenoxamine; ... Pay-Per-View - Georgia Code - Loislaw

California Code of Regulations - § 27:27001. Chemicals Known to the …  -  Jul 30, 2008
2000 Chlorothalonil 1897-45-6 January 1, 1989 Chlorotrianisene 569-57-3 September 1, 1996 Chlorozotocin 54749-90-5 January 1, 1992 Chromium (hexavalent ... Pay-Per-View - California Code of Regulations - Loislaw

Embolism; Cerebral embolism occurred after transcatheter arterial …  -  Nov 22, 2005
Keywords: Tokyo, Japan, Angiology, Basilar Ganglia, Cardiology, Cerebral Lipidol Embolism, Chlorotrianisene, Fat Embolism, Hepatocellular Cancer, ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones

Brand Names/Synonyms:
Chlorotrianisene is also known by the following brand names and/or synonymsAnisene; CCRIS 4769; CTA; Chloortrianisestrol; Chlorestrolo; Chlorotrianisene; Chlorotrianisene [Ban:Inn]; Chlorotrianisenum [Inn-Latin]; Chlorotrianisine; Chlorotrianizen; Chlorotrisin; Chlortrianisen; Chlortrianisene; Chlortrianisenum; Chlortrianisestrol; Chlortrianisoestrolum; Chlortrianizen; Clorestrolo; Clorotrianisene [Dcit]; Clorotrianiseno [Inn-Spanish]; Clorotrisin; HSDB 3302; Hormonisene; Khlortrianizen; Merbentul; Metace; NSC-10108; Rianil; Tace; Tace-Fn; Trianisestrol

Drug Category:
Chlorotrianisene is categorized under the following by the FDA: Antineoplastic Agents; Estrogens, Non-Steroidal; ATC:G03CA06

Dosage Forms:
CAPSULE (12 mg)

Absorption:
Absorption following oral administration is rapid.

Interactions:
[an error occurred while processing this directive]

Chemical IUPAC Name:
1-[2-chloro-1,2-bis(4-methoxyphenyl)-ethenyl]-4-methoxy-benzene

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.